GlassScriptPhysician profile
Shomari D Thompson
NPI 1194286252
$2,427.60
in general payments reported to CMS, 2019-2025
18 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.24 · 2022: $119 · 2023: $275 · 2024: $698 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.96 | 2023-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $292.36 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $240.08 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.31 | 2024 | Jardiance |
| Amgen INC. | $132.35 | 2024-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.23 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $106.28 | 2025 | Breztri |
| Genzyme Corporation | $97.60 | 2025 | |
| Novo Nordisk INC | $76.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $74.85 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Medtronic, INC. | $51.97 | 2022-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Corcept Therapeutics | $43.78 | 2024-2025 | Korlym |
| Insulet Corporation | $41.48 | 2024-2025 | Omnipod |
| Advanced Respiratory, INC | $40.24 | 2020 | |
| Axsome Therapeutics, INC. | $30.78 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.37 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.24 | 2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $16.04 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shomari Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.